primary studies published RCT Growth hormone normalizes pubertal onset in children with cystic fibrosis. Year: 2006 Date: 2009 Author: Vanderwel M Source J Pediatr Endocrinol Metab. 2006 Mar;19(3):237-44. Study design (if review, criteria of inclusion for studies) RCT, parallel group, multicentre. Participants 78 people with CF; 42 children (8 - 17 yrs) and 36 adults (18 - 42 yrs). Interventions 1. TOBI® (300 mg/5 ml delivered by PARI LC PLUS); 2. Tobramycin PARI (150 mg/1.5 ml, delivered by an investigational eFlow), twice daily for 28 days. Outcome measures Sputum concentration of tobramycin at 7 days of use. Serum levels of tobramycin at 7 days of use. Adverse events. Nebulisation time.